Table 2.

Expansion Cohort Genomic Alterations and Treatment Response

Patient	Mutation	Time on Therapy (Days)	PFS (Months)	OS (Months)	Reason for Study Discontinuation	8-Week Imaging
1	TSC1 Y185*	53	1.0	2.6	Progression	N/A
2	TSC1 R424Nfs*	55	1.7	9.2	Progression	Y; PDǂ
3	PI3K E542K	28	1.9	20.3	Toxicity	N/A
4	TSC1 Q516*	16	0.6ǂǂ	1.7	Progression	N/A

^ǂNew non-target lesions consistent with progression of disease

^ǂǂPatient ineligible for primary endpoint evaluation due to receiving <1 cycle of therapy